Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Tampere University30 enrolled

Overview

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

bicalutamide (Casodex), goserelin (Zoladex)DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers 2. Patients who are scheduled for radical prostatectomy with curative intents

Locations (1)

TUCH

Tampere, Finland

Outcomes

Primary Outcomes

Proliferation by Ki67,

apoptosis marker (TUNEL assay),

Gleason score

Secondary Outcomes

expression of known androgen-regulated genes,

biomarkers of apoptotic pathway,

(novel) genomic transcripts

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.